Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

As the DeepSeek craze ignites a sell-off in the tech sector, investors are weighing the implications of the downturn in the long term.

Eyeing an expected leap in demand for contrast media—used in X-rays, CT scans and more—GE HealthCare is upping its stake in the Emerald Isle. | GE HealthCare is pumping $138 million into its ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered growth needed to ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.